Who are Hi-dose iv MgSO4's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Namenda, Felbatol, QUINIDINE, Methadone Hydrochloride, Nitrous oxide gas for inhalation, S-Ketamine 0.5.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hi-dose-iv-mgso4.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Hi-dose iv MgSO4 — Competitive Intelligence Brief

Hi-dose iv MgSO4 (Hi-dose iv MgSO4) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NMDA receptor antagonist / Neuroprotective agent. Area: Neurology.

phase 3 NMDA receptor antagonist / Neuroprotective agent NMDA receptor Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Hi-dose iv MgSO4 (Hi-dose iv MgSO4) — Hamad Medical Corporation. High-dose intravenous magnesium sulfate acts as a neuroprotective agent and anticonvulsant by blocking N-methyl-D-aspartate (NMDA) receptors and stabilizing neuronal membranes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Hi-dose iv MgSO4 TARGET	Hi-dose iv MgSO4	Hamad Medical Corporation	phase 3	NMDA receptor antagonist / Neuroprotective agent	NMDA receptor
Namenda	MEMANTINE	AbbVie	marketed	N-methyl-D-aspartate Receptor Antagonist	Glutamate NMDA receptor; GRIN1/GRIN2A	2003-01-01
Felbatol	FELBAMATE	Mylan Speciality Lp	marketed	Anti-epileptic Agent [EPC]	NMDA receptor-ionophore complex	1993-01-01
QUINIDINE	QUINIDINE		marketed		sigma-1 receptor, NMDA receptor, CYP2D6	1950-01-01
Methadone Hydrochloride	METHADONE	Specgx Llc	marketed	Opioid Agonist	mu-opioid receptors, NMDA receptor	1947-01-01
Nitrous oxide gas for inhalation	Nitrous oxide gas for inhalation	Unity Health Toronto	marketed	Dissociative anesthetic	NMDA receptor
S-Ketamine 0.5	S-Ketamine 0.5	Turku University Hospital	marketed	NMDA receptor antagonist	NMDA receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NMDA receptor antagonist / Neuroprotective agent class)

Hamad Medical Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hi-dose iv MgSO4 — Competitive Intelligence Brief. https://druglandscape.com/ci/hi-dose-iv-mgso4. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab